CGMAB
Dead / Abandoned — Abandoned — no statement of use filed (as of 28 Oct 2019)
What this means for you
This application is over — abandoned 28 Oct 2019. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87818647
- Mark type
- Word mark
- Filed
- 02 Mar 2018
- Published for opposition
- 31 Jul 2018
- Abandoned
- 28 Oct 2019
- Attorney of record
- Alex Patel
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Chemical preparations for pharmaceutical or medical purposes, namely, for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Biological preparations for the treatment of cancer; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Ferments for pharmaceutical purposes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Medical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Tumor suppressing agents; Clinical medical reagents; Anti-diabetic pharmaceuticals; Anti-cancer preparations; Cellular function activating agents for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing
Owner
- Phanes Therapeutics, Inc., SAN DIEGO, CA, US
- Phanes Therapeutics, Inc., SAN DIEGO, CA, US
Prosecution history
- 28 Oct 2019 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 28 Oct 2019 — ABANDONMENT - NO USE STATEMENT FILED
- 13 Mar 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Mar 2019 — SOU EXTENSION 1 GRANTED
- 11 Mar 2019 — SOU EXTENSION 1 FILED
- 11 Mar 2019 — SOU TEAS EXTENSION RECEIVED
- 25 Sept 2018 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 31 Jul 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Jul 2018 — PUBLISHED FOR OPPOSITION
- 11 Jul 2018 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Jun 2018 — ASSIGNED TO LIE
- 14 Jun 2018 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Jun 2018 — EXAMINER'S AMENDMENT ENTERED
- 14 Jun 2018 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 14 Jun 2018 — EXAMINERS AMENDMENT E-MAILED